Home » Uncategorized » Top Biotech News (14 July 2026)

Top Biotech News (14 July 2026)

Which ‘AI scientist’ suits your lab? A guide for the perplexed

Summary:

A new generation of AI scientists including Claude Science, Co-Scientist, and Biomni is transforming research workflows by accelerating analysis, hypothesis generation, and discovery, while highlighting the continuing importance of human expertise, validation, and scientific judgment.

Biotech startup funding gap widens despite rebound in VC investment

Summary:

Biotech funding rebounded in 2026, but investment increasingly favored later-stage companies, widening the funding gap for seed-stage startups and emerging therapeutic platforms.

AstraZeneca stock drops 9% after heart drug trial miss deals rare blow to pharma powerhouse

Summary:

AstraZeneca’s late-stage Wainua trial failed in ATTR cardiomyopathy, raising concerns over management credibility while strengthening competitors’ positions in the market.

Agenus scraps phase 3 colorectal study after 3 months to narrow focus to colon cancer

Summary:

Agenus discontinued its phase 3 metastatic colorectal cancer trial to concentrate resources on MSS colon cancer, aiming to unlock immunotherapy benefits in this historically resistant disease setting.

ARPA-H awards up to $160M to scientists developing custom genetic medicines

Summary:

ARPA-H will invest up to $160 million to accelerate personalized genetic medicines, supporting custom therapies and umbrella trials for rare pediatric diseases.

Subscribe
to the latest updates in the newsletter

Related Solutions

  • Disease Modeling
  • Oncology
  • Organoid
  • Cosmetics
  • OECD TG
  • Zebrafish
  • Bioinfomatics
  • Live&3D Imaging
  • Molecular biology
  • Spatial Biology
Technical Service

Next Articles

There are no further posts.

Thank you for your submission.

Our team has received your request and will get back to you shortly with tailored workflows and relevant case studies for your ADC efficacy and toxicity evaluation needs.
If you do not receive our confirmation email, kindly check your spam or junk folder.

Thank you for your insterest

You can now download the file.

Connect with Us